After Committee Hearing, Warren Presses RFK Jr. on Commitments Involving TrumpRx Scams, Big Pharma Deals

After Committee Hearing, Warren Presses RFK Jr. on Commitments Involving TrumpRx Scams, Big Pharma Deals

"Your responses to questions about the Administration's deals with pharmaceutical manufacturers raise troubling questions about President Trump's failure to reduce drug prices for Americans. I write to follow up on the commitments you made during that exchange."

Text of Letter (PDF)

Washington, D.C. - U.S. Senator Elizabeth Warren pressed Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on multiple commitments she secured during an exchange in last week's Senate Finance Committee hearing.

"Your responses to questions about the Administration's deals with pharmaceutical manufacturers raise troubling questions about President Trump's failure to reduce drug prices for Americans," wrote Senator Warren. "I write to follow up on the commitments you made during that exchange."

In the hearing, Secretary Kennedy confirmed that, for many drugs, Americans are being steered to expensive, brand name drugs on TrumpRx despite the availability of identical generics for much lower prices at local pharmacies. Secretary Kennedy appeared to agree that TrumpRx is misleading consumers, saying that "people should be buying the generic" and that, in the future, "we will be directing them to the generic."

"This answer revealed exactly my concern - that TrumpRx is acting as a conduit for Big Pharma to steer consumers to expensive brand name drugs when cheaper generics are available," wrote Senator Warren.

Senator Warren warned that there is currently no language on TrumpRx to "direct [Americans] to the generic" option, as the Secretary promised, and pressed him to fill the gap immediately.

Senator Warren further questioned Secretary Kennedy on the Trump Administration's sweetheart deals with Big Pharma, securing a commitment from Kennedy to make the details of the deals public.

"You and I discussed the extent to which President Trump has been swindled by Big Pharma, giving them handouts worth billions of dollars in exchange for what appears to be no meaningful concessions for consumers," wrote Senator Warren.

Kennedy indicated that his team negotiated the dealsand, after pressure from Senator Warren to publicly release the details, confirmed that he is "happy to make the deals available, except for proprietary information and trade secrets."

Senator Warren also asked Secretary Kennedy to explain his claim that "millions" of people are using TrumpRx and requested additional information on the public's utilization of TrumpRx.

Senator Warren seeks written responses from Secretary Kennedy to eight questions:

1. Please provide copies of all negotiated deals made with drug manufacturers that list their drugs on TrumpRx. For any information that is redacted because you claim it is confidential or trade secret, please provide a clear explanation for doing so.

2. Why did HHS publish the TrumpRx website without a clear indication that cheaper generic drugs may be available?

3. Did the pharmaceutical companies with whom President Trump struck deals request that the website omit information about the availability of cheaper generic options?

4. When will you update the website to indicate that "people should be buying generic [drugs]" and "direct[] them to the generic"?

5. What form will such indications and directions take?

6. How many Americans have visited the TrumpRx website since February 5, 2026?

7. How many prescriptions have been purchased by Americans using TrumpRx coupons?

8. Please provide a table indicating how many prescriptions have been filled for each of the 86 drugs that are currently listed on TrumpRx.

To ensure that Secretary Kennedy will meet the commitments he made during the hearing and to address the additional concerns raised by his testimony, the Senator asked for a response no later than May 28, 2026.

Senator Warren has led efforts to push back against Big Pharma and use every tool available in government to lower drug prices:

• In April 2026, at a hearing of the Senate Finance Committee, U.S. Senator Elizabeth Warren pressed Secretary of the Department of Health and Human Services (HHS) Robert F. Kennedy Jr. on TrumpRx, revealing how President Trump's marquee drug pricing effort often provides higher prices for Americans while boosting Big Pharma's bottom line.

• In April 2026, U.S. Senator Elizabeth Warren, a member of the Senate Finance Committee; Ron Wyden (D-Ore.), Ranking Member of the Senate Finance Committee; and 18 Senate Democrats introduced new legislation to force the Trump Administration to disclose the terms of deals signed with more than a dozen of the largest pharmaceutical companies and conduct an independent analysis to determine whether American families will see lower prices from the deals.

• In February 2026, Senators Elizabeth Warren and Josh Hawley (R-Mo.) introduced the Break Up Big Medicine Act to address rampant consolidation in the health care industry that drives up prices, squashes competition, and fuels corporate greed.

• In November 2025, Senator Elizabeth Warren, Senate Minority Leader Chuck Schumer (D-N.Y.), and Finance Committee Ranking Member Ron Wyden (D-Ore.) led 25 Senate Democrats in slamming the Trump administration for its failure to address rising health care costs for American families.

• In June 2025, Senator Elizabeth Warren, a member of the Senate Finance Committee, and Representative Jan Schakowsky (D-Ill.) wrote to Abbvie, Pfizer, Amgen, Merck, and Johnson & Johnson, calling them out for taking advantage of tax loopholes created by President Trump's 2017 tax bill and lobbying for even more tax giveaways.

• In March 2025, Senator Elizabeth Warren, along with Senate Finance Ranking Member Ron Wyden (D-Ore.) and Senate Health, Education, Labor, and Pensions (HELP) Ranking Member Bernie Sanders (I-Vt.), pressed Department of Health and Human Services Secretary Robert F. Kennedy Jr. on his promises to "clean up corruption" and "stop the revolving door between industry and government," following reports that Kennedy attended multiple "million-dollar" dinners with Big Pharma executives at President Trump's Mar-a-Lago club.

###